C4'-Substituted-2-Deoxyadenosine Analogs and Methods of Treating HIV
Description of Invention:
The invention describes a new use for C4'-methyl-2-dexoyadenosine, a nucleoside analog that has significant activity against HIV-1 and most strains of HIV previously shown to be resistant to other reverse transcriptase nucleoside inhibitor treatments. In vitro experimental results show substantial anti-HIV activity (blocked infectivity) with no observable cytotoxicity in cell culture. Mechanistic studies indicate that this compound blocks DNA synthesis by reverse transcriptase.
Applications:
Treatment and prevention of HIV infection
Advantages:
Nucleoside analog against HIV-1 reverse transcriptase with no observable cytotoxicity in cell culture
Potential new treatment for HIV-1 infections including infections by strains of HIV-1 that are resistant to nucleoside reverse transcriptase inhibitors
Development Status:
In vitro data can be provided upon request
Market:
Therapeutic for the treatment and/or prevention of HIV infection
Patent Status:
DHHS Reference No. E-012-2008/0 --
U.S. Provisional Application No. 61/002,711 filed 09 Nov 2007
Relevant Publication: Meeting Abstract: 8th Annual Symposium for Antiviral Resistance in Richmond, VA, November 11-14, 2007 (Can be provided upon request)
Licensing Status: Available for exclusive or non-exclusive licensing.
Collaborative Research Opportunity:
The National Cancer Institute HIV Drug Resistance Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize C4' methyl- and C4'-ethyl-substituted-2-deoxyadenosine analogs Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
For Additional Information Please Contact: Sally Hu PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5606
Email: hus@mail.nih.gov
Fax: (301) 402-0220
